Lenvatinib对铂难治性转移性高级别胸腺黏液表皮样癌的持久疗效：1例报告

IF 3.5 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2025-10-01 DOI:10.1016/j.jtocrr.2025.100894

Noa Amin PhD, MRCP , Thanika Ketpueak DM , Simon Jordan MBBCh, MD , Andrew G. Nicholson DM, FRCPath , Yu Zhi Zhang MBBS, PhD, FRCPath , Sanjay Popat PhD FRCP

{"title":"Lenvatinib对铂难治性转移性高级别胸腺黏液表皮样癌的持久疗效：1例报告","authors":"Noa Amin PhD, MRCP , Thanika Ketpueak DM , Simon Jordan MBBCh, MD , Andrew G. Nicholson DM, FRCPath , Yu Zhi Zhang MBBS, PhD, FRCPath , Sanjay Popat PhD FRCP","doi":"10.1016/j.jtocrr.2025.100894","DOIUrl":null,"url":null,"abstract":"<div><div>Thymic mucoepidermoid carcinoma (MEC) is a rare thymic carcinoma subtype. Current metastatic thymic carcinoma guidelines recommend first-line platinum-based chemotherapy. However, evidence suggests that MECs, including those of the lung and salivary gland, are chemorefractory, highlighting a more nuanced approach to systemic therapy decision-making. Here, we report a case of durable partial response to second-line lenvatinib in a patient with metastatic high-grade thymic MEC, refractory to first-line platinum-based chemotherapy, suggesting a potentially preferred first-line role for lenvatinib for this subtype.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 10","pages":"Article 100894"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report\",\"authors\":\"Noa Amin PhD, MRCP , Thanika Ketpueak DM , Simon Jordan MBBCh, MD , Andrew G. Nicholson DM, FRCPath , Yu Zhi Zhang MBBS, PhD, FRCPath , Sanjay Popat PhD FRCP\",\"doi\":\"10.1016/j.jtocrr.2025.100894\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Thymic mucoepidermoid carcinoma (MEC) is a rare thymic carcinoma subtype. Current metastatic thymic carcinoma guidelines recommend first-line platinum-based chemotherapy. However, evidence suggests that MECs, including those of the lung and salivary gland, are chemorefractory, highlighting a more nuanced approach to systemic therapy decision-making. Here, we report a case of durable partial response to second-line lenvatinib in a patient with metastatic high-grade thymic MEC, refractory to first-line platinum-based chemotherapy, suggesting a potentially preferred first-line role for lenvatinib for this subtype.</div></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"6 10\",\"pages\":\"Article 100894\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364325001122\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364325001122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胸腺粘液表皮样癌（MEC）是一种罕见的胸腺癌亚型。目前的转移性胸腺癌指南推荐一线铂基化疗。然而，有证据表明，包括肺和唾液腺在内的mec是化疗难治性的，这突出了更细致入微的系统性治疗决策方法。在这里，我们报告了一例转移性高级别胸腺MEC患者对二线lenvatinib的持久部分反应，对一线铂基化疗难治，提示lenvatinib在一线治疗该亚型的潜在首选作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report

Thymic mucoepidermoid carcinoma (MEC) is a rare thymic carcinoma subtype. Current metastatic thymic carcinoma guidelines recommend first-line platinum-based chemotherapy. However, evidence suggests that MECs, including those of the lung and salivary gland, are chemorefractory, highlighting a more nuanced approach to systemic therapy decision-making. Here, we report a case of durable partial response to second-line lenvatinib in a patient with metastatic high-grade thymic MEC, refractory to first-line platinum-based chemotherapy, suggesting a potentially preferred first-line role for lenvatinib for this subtype.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊